ClinicalTrials.gg
CompletedNCT03883646MITUpdated Nov 13, 2026Results posted

Mindfulness for Alcohol Abusing Offenders

An interventional study of Mindfulness and Relapse Prevention in Alcohol Abuse and Criminal Behavior, sponsored by The Mind Research Network. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by The Mind Research Network · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jul 2018, registered Mar 2019).
Updated Nov 13, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,076 studies in Alcoholism with a site in United States — 190 open to participants now, 230 under way, 16 of them phase 3. Alcoholism · United States.

Enrollment
236th of 992
176 · median 80
Started
2018
with 49 others
No phase
436 of 1,076
85 open now
Registered
656th of 1,076
by date

Among the 1,076 studies in Alcoholism with a site in United States, this one is the 236th largest by enrollment of the 992 interventional ones that give a count, is one of 50 that started in 2018, is one of 436 with no phase, and was the 656th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

190 of the 1,076 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,076 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

Over half of state and federal prisoners meet clinical criteria for alcohol abuse or dependence, and after release from prison, over three-quarters of offenders are re-arrested within five years. Thus, there is a critical need for more effective interventions that could help disrupt this insidious cycle of alcohol abuse, criminal behavior, and incarceration. This project will support the development and evaluation of a mindfulness intervention for female prison inmates that will target key neuropsychological vulnerabilities that are associated with relapse and recidivism.

Read the detailed description

The pernicious link between substance abuse and criminal behavior imposes major costs to society, totaling billions of dollars in the U.S. annually. There is a critical need for more effective interventions to counteract the high rates of relapse and recidivism in alcohol and substance abusing criminal offenders. Periods of offender incarceration provide a unique opportunity to develop and deploy such interventions. Progress in intervention development could be achieved by targeting specific cognitive and affective vulnerabilities that are common among substance abusing criminal offenders. Preliminary studies suggest that meditative or mindfulness interventions may confer significant psychological and behavioral benefits to inmates. However, the mechanisms and extent of intervention efficacy are unclear, as these previous studies have been beset by a number of methodological limitations. Moreover, to date no study has examined the neurobiological mechanisms that relate to treatment success in this population. NIAAA has recently made a program call to address these issues (PA-15-299). Here we answer this program call and propose to undertake a rigorous and comprehensive longitudinal study of mindfulness treatment of alcohol and substance use disorders among female inmates. This project will randomly assign over 400 female inmates to a mindfulness or relapse prevention training course, and both will be compared against a no treatment control. The mindfulness intervention will be tailored to address two key neuropsychological deficits in alcohol abusing criminal offenders: impulsivity and craving. We will test hypotheses about the neural changes over time with treatment to elucidate mechanisms of change. We will obtain estimates of "real-world" efficacy of the intervention by collecting outcome measures in prison (conduct reports) and following release (alcohol use relapse and antisocial behavior). This project takes advantage of a unique, longstanding partnership between the research team and the states of New Mexico and Wisconsin Correction Departments that allows collection of comprehensive assessment data from inmates during incarceration, including brain imaging data with a mobile MRI scanner, as well as access to post-release outcomes and relapse data. Completion of these aims is a critical step for implementing and evaluating a promising mindfulness intervention for this high-risk population. The proposed research will also begin to elucidate the psychological and neurobiological mechanisms of the treatment. These results will thus significantly advance a program of research seeking to translate the growing knowledge of neuropsychological deficits into more targeted and effective treatments for alcohol and substance abuse problems in criminal offenders.

03

Conditions studied

  • Alcohol Abuse
  • Criminal Behavior
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age
  • Alcohol Use Disorder
  • Female (biological sex at birth)
  • Time to release from incarceration > 3 months
  • 5th grade or higher reading level
  • Able to speak and understand English

Exclusion criteria

Exclusion Criteria:

  • Uncorrectable auditory or visual deficits
  • Intelligence Quotient score below 70
  • History of dementia or other cognitive disability
  • Current psychotic disorder (chronic schizophrenia or schizoaffective disorder and/or active psychotic symptoms)
  • Major medical illness or Central Nervous System disease
  • MRI incompatibility (e.g., metal in body)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Mindfulness

    Mindfulness

    Behavioral: Mindfulness

  • Experimental
    Relapse Prevention

    Behavioral: Relapse Prevention

  • No intervention
    Waitlist Control
  • No intervention
    Treatment as Usual

Interventions

  • BehavioralMindfulness

    Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).

  • BehavioralRelapse Prevention

    Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).

06

What researchers measure

Primary outcomes

  1. Change From Baseline Alcohol Craving

    Penn Alcohol Craving Scale. 5-item, self-report measure assessing frequency, intensity, and duration of craving, and overall rating of craving for the previous week. Total score range 0-30. Higher scores indicate higher craving.

    Time frame: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.

  2. Change From Baseline Daily Depression

    Beck Depression Inventory-II (BDI-II). Assesses participants' self-reported depression in the past two weeks. Data for total scores is provided (range: 0-63). Higher scores indicate increased severity of depressive symptoms.

    Time frame: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.

  3. Change From Baseline Perception of Quality of Life

    World Health Organization Quality of Life - Brief (WHOQOL-BREF). 26-item, self-report measure assessing how individuals perceive their quality of life across domains. Data for psychological health is reported (range: 6-30). Higher scores indicate increased psychological health.

    Time frame: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.

  4. Proportion of Participants Who Were Not Arrested Following Release From Incarceration

    Arrests on misdemeanor and felony charges were the categories used to track criminal behavior in the study participants. To evaluate the effect of the treatment on criminal behavior, we used official state databases to track criminal activity for participants who were released from incarceration post-treatment.

    Time frame: 30 months following release from incarceration; misdemeanor and felony arrests were cataloged across the treatment arms.

  5. Participant Reflections on Their Treatment Program

    During the last session of treatment, participants were given a "Reflections on the Course" handout, where they provided feedback on the treatment they received. Participants were asked to provide a rating to the following question: * Question 1: On a scale of 1 (not at all) to 10 (very), how important has this program been to you?

    Time frame: Post-treatment (immediately after 8-week treatment ended)

  6. Investigate Behavioral and Neural Changes Related to Alcohol Craving During Treatment

    Salience Alcohol Task (SAT): A drug-cue reactivity functional Magnetic Resonance Imaging (fMRI) task, whereby participants viewed different stimuli (i.e., alcohol cues, negatively valanced stimuli, or neutrally valanced stimuli). After seeing each image, participants were asked to respond to which type of image they saw (i.e., alcohol cues, neutral cues, and negatively valanced cues). Participants completed this task pre-/post-treatment. Independent component analysis was used to extract brain regions related to alcohol cue reactivity, in order to assess functional connectivity changes related to treatment between these regions. Values below represent positive change in z-scores (post - pre-treatment) related to increased functional network connectivity between the anterior cingulate cortex and anterior insula, regions commonly involved in salience detection. A z-score of 0 represents the population mean. All four groups showed increased functional connectivity with z-scores above 0.

    Time frame: Baseline (before treatment) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given scans at the same timeframe as those who participated in treatment.

07

Results

Posted Nov 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneMindfulnessRelapse PreventionWaitlist ControlTreatment as Usual
Started8077811
Completed6167811
Not completed191000

Outcome measures

PrimaryChange From Baseline Alcohol Craving

Penn Alcohol Craving Scale. 5-item, self-report measure assessing frequency, intensity, and duration of craving, and overall rating of craving for the previous week. Total score range 0-30. Higher scores indicate higher craving.

Time frame:
Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
Reported as:
Mean · score on a scale
Change From Baseline Alcohol Craving
score on a scaleMindfulnessRelapse PreventionWaitlist ControlTreatment as Usual
Change From Baseline Alcohol Craving-2.73 ± 6.47-1.75 ± 6.34-4.29 ± 8.771.88 ± 6.08
PrimaryChange From Baseline Daily Depression

Beck Depression Inventory-II (BDI-II). Assesses participants' self-reported depression in the past two weeks. Data for total scores is provided (range: 0-63). Higher scores indicate increased severity of depressive symptoms.

Time frame:
Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
Reported as:
Mean · score on a scale
Change From Baseline Daily Depression
score on a scaleMindfulnessRelapse PreventionWaitlist ControlTreatment as Usual
Change From Baseline Daily Depression-5.29 ± 7.92-7.12 ± 9.88-15.43 ± 10.474.00 ± 10.07
PrimaryChange From Baseline Perception of Quality of Life

World Health Organization Quality of Life - Brief (WHOQOL-BREF). 26-item, self-report measure assessing how individuals perceive their quality of life across domains. Data for psychological health is reported (range: 6-30). Higher scores indicate increased psychological health.

Time frame:
Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
Reported as:
Mean · score on a scale
Change From Baseline Perception of Quality of Life
score on a scaleMindfulnessRelapse PreventionWaitlist ControlTreatment as Usual
Change From Baseline Perception of Quality of Life0.56 ± 1.620.44 ± 1.520.76 ± 1.050.25 ± 2.28
PrimaryProportion of Participants Who Were Not Arrested Following Release From Incarceration

Arrests on misdemeanor and felony charges were the categories used to track criminal behavior in the study participants. To evaluate the effect of the treatment on criminal behavior, we used official state databases to track criminal activity for participants who were released from incarceration post-treatment.

Time frame:
30 months following release from incarceration; misdemeanor and felony arrests were cataloged across the treatment arms.
Reported as:
Number · proportion of participants
Proportion of Participants Who Were Not Arrested Following Release From Incarceration
proportion of participantsMindfulnessRelapse PreventionWaitlist ControlTreatment as Usual
Proportion of Participants Who Were Not Arrested Following Release From Incarceration0.873 (0.76 to 1.00)0.689 (0.53 to 0.89)0.857 (0.63 to 1.00)1.00 (1.00 to 1.00)
PrimaryParticipant Reflections on Their Treatment Program

During the last session of treatment, participants were given a "Reflections on the Course" handout, where they provided feedback on the treatment they received. Participants were asked to provide a rating to the following question: * Question 1: On a scale of 1 (not at all) to 10 (very), how important has this program been to you?

Time frame:
Post-treatment (immediately after 8-week treatment ended)
Reported as:
Mean · score on a scale
Participant Reflections on Their Treatment Program
score on a scaleMindfulnessRelapse PreventionWaitlist ControlTreatment as Usual
Participant Reflections on Their Treatment Program9.00 ± 1.339.03 ± 1.10——
PrimaryInvestigate Behavioral and Neural Changes Related to Alcohol Craving During Treatment

Salience Alcohol Task (SAT): A drug-cue reactivity functional Magnetic Resonance Imaging (fMRI) task, whereby participants viewed different stimuli (i.e., alcohol cues, negatively valanced stimuli, or neutrally valanced stimuli). After seeing each image, participants were asked to respond to which type of image they saw (i.e., alcohol cues, neutral cues, and negatively valanced cues). Participants completed this task pre-/post-treatment. Independent component analysis was used to extract brain regions related to alcohol cue reactivity, in order to assess functional connectivity changes related to treatment between these regions. Values below represent positive change in z-scores (post - pre-treatment) related to increased functional network connectivity between the anterior cingulate cortex and anterior insula, regions commonly involved in salience detection. A z-score of 0 represents the population mean. All four groups showed increased functional connectivity with z-scores above 0.

Time frame:
Baseline (before treatment) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given scans at the same timeframe as those who participated in treatment.
Reported as:
Mean · z-scored functional connectivity value
Investigate Behavioral and Neural Changes Related to Alcohol Craving During Treatment
z-scored functional connectivity valueMindfulnessRelapse PreventionWaitlist ControlTreatment as Usual
Investigate Behavioral and Neural Changes Related to Alcohol Craving During Treatment0.05 ± 0.430.01 ± 0.330.04 ± 0.360.06 ± 0.48

Adverse events

Collected over We monitored participants from the time they were consented to the study through their active study participation (3 years).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mindfulness0/80 (0%)0/80 (0%)0/80 (0%)
Relapse Prevention0/77 (0%)0/77 (0%)0/77 (0%)
Waitlist Control0/8 (0%)0/8 (0%)0/8 (0%)
Treatment as Usual0/11 (0%)0/11 (0%)0/11 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)MindfulnessRelapse PreventionWaitlist ControlTreatment as UsualTotal
Mean35.88 ± 8.3237.75 ± 8.4732.38 ± 3.5037.82 ± 8.2636.66 ± 8.28
Sex: Female, Male
Sex: Female, Male(Participants)MindfulnessRelapse PreventionWaitlist ControlTreatment as UsualTotal
Female8077811176
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MindfulnessRelapse PreventionWaitlist ControlTreatment as UsualTotal
Hispanic or Latino36365279
Not Hispanic or Latino44413997
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MindfulnessRelapse PreventionWaitlist ControlTreatment as UsualTotal
American Indian or Alaska Native1192022
Asian11002
Native Hawaiian or Other Pacific Islander00000
Black or African American551112
White4844310105
More than one race31004
Unknown or Not Reported12172031
Region of Enrollment
Region of Enrollment(participants)MindfulnessRelapse PreventionWaitlist ControlTreatment as UsualTotal
United States8077811176
08

Study locations

1 site
  • The Mind Research Network
    Albuquerque, New Mexico 87106, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Apr 2025, 81 months.

Results were first posted in Nov 2026, 1 year 6 months after primary completion.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 81 months is above that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2019
First posted
Mar 21, 2019
StartActual
Jul 1, 2018
Primary completionActual
Apr 30, 2025
CompletionActual
Apr 30, 2025
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Enrollment
392→176
Nov 13, 2026
Primary outcomes
2 edited, 4 added, 2 removed
What changed in the outcomes
  • EditedChange from baseline alcohol cravingFrom Baseline Alcohol CravingTime frame: 4 weeks, 8 weeks, and after release from incarceration (every 3 months) → Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
  • EditedChange from baseline daily alcohol consumptionFrom Baseline Daily DepressionTime frame: Every 3 months after release from incarceration → Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
  • AddedChange From Baseline Perception of Quality of LifeTime frame: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
  • AddedProportion of Participants Who Were Not Arrested Following Release From IncarcerationTime frame: 30 months following release from incarceration; misdemeanor and felony arrests were cataloged across the treatment arms.
  • AddedParticipant Reflections on Their Treatment ProgramTime frame: Post-treatment (immediately after 8-week treatment ended)
  • AddedInvestigate Behavioral and Neural Changes Related to Alcohol Craving During TreatmentTime frame: Baseline (before treatment) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given scans at the same timeframe as those who participated in treatment.
  • RemovedChange from baseline temptation to drink alcoholTime frame: 4 weeks, 8 weeks, and after release from incarceration (every 3 months)
  • RemovedCriminal BehaviorTime frame: An average of six months after release from incarceration
Nov 13, 2026
Documents
Show all 1 update
  1. Nov 13, 2026
    Results posted
    Enrollment 392→176
    Primary outcomes 2 edited, 4 added, 2 removed
    What changed in the outcomes
    • EditedChange from baseline alcohol cravingFrom Baseline Alcohol CravingTime frame: 4 weeks, 8 weeks, and after release from incarceration (every 3 months) → Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
    • EditedChange from baseline daily alcohol consumptionFrom Baseline Daily DepressionTime frame: Every 3 months after release from incarceration → Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
    • AddedChange From Baseline Perception of Quality of LifeTime frame: Baseline (before treatment started) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given assessments at the same timeframe as those who participated in treatment.
    • AddedProportion of Participants Who Were Not Arrested Following Release From IncarcerationTime frame: 30 months following release from incarceration; misdemeanor and felony arrests were cataloged across the treatment arms.
    • AddedParticipant Reflections on Their Treatment ProgramTime frame: Post-treatment (immediately after 8-week treatment ended)
    • AddedInvestigate Behavioral and Neural Changes Related to Alcohol Craving During TreatmentTime frame: Baseline (before treatment) and Post-treatment (immediately after 8-week treatment ended). Waitlist and Treatment as Usual participants were given scans at the same timeframe as those who participated in treatment.
    • RemovedChange from baseline temptation to drink alcoholTime frame: 4 weeks, 8 weeks, and after release from incarceration (every 3 months)
    • RemovedCriminal BehaviorTime frame: An average of six months after release from incarceration
    + 3 other changes: verification date, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03883646
Lead sponsor
The Mind Research Network
Responsible party
Kent Kiehl (Professor of Psychology, Neuroscience and Law, Executive Science Officer, The Mind Research Network) — Principal investigator
First posted
Mar 21, 2019
Start date
Jul 1, 2018
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion